• SELECT SITE CURRENCY
Select a currency for use throughout the site
DRG Insights: Hepatitis C (G7)
Decision Resources, Inc, May 2012, Pages: 52
DRG Insights takes the most relevant information and insights from across our portfolio for BioPharma and Med-Tech products and delivers the insight heavy perspective that you need to generate better ideas and deliver more successful campaigns and initiatives. Hepatitis C virus (HCV) is marked by a relatively large prevalent population and high unmet medical need due to the suboptimal efficacy of current therapy.
This high unmet need makes HCV one of the most active areas of drug development within infectious diseases. The protease and polymerase inhibitors are the most promising classes in development, and we anticipate these agents will change the standard of care soon after they are introduced into the market.
We expect the HCV market to greatly expand in the coming years due, in large measure, to the entry of novel drugs and their impact on both treatment rates and the re-treatment of nonresponders.
Executive Summary Current Market Landscape
Etiology & Pathophysiology
Select Drug Targets
Growth Drivers & Constraints
Country Specific Decision Trees
Comparison of Key Agents
Expert Insight on Prescribing Trends
Importance of Drug Attributes in Prescribing Decisions
Pricing & Reimbursement
Factors Influencing Pharmacy Director Tier Placement Decisions
Accessibility and Cost Hurdles
Important Endpoints in Prescribing Decisions
2010 and 2010 sales and Market Share